📊 NKTR Key Takeaways
Is Nektar Therapeutics (NKTR) a Good Investment?
NKTR is in severe financial distress with revenue collapsing 43.9% YoY to only $10.9M while burning $44.3M in operating cash annually. Operating margins of -359.6% and net margins of -413.4% indicate a fundamentally broken business model with minimal profitability at the gross level (5.7% margin). Despite adequate short-term liquidity ($149.6M cash), the company faces an unsustainable 3-4 year cash runway at current burn rates without significant operational turnaround.
Fundamentals deteriorated sharply with revenue down 43.9% YoY, a near-zero gross margin, and deeply negative operating and net margins, signaling an unsustainable core model. Cash burn of $208.5M against only $15.1M in cash and leverage of 1.49x D/E create acute financing and going-concern risk. Without rapid improvement in gross margin and revenue or material cost restructuring, external financing or distress is likely.
Nektar Therapeutics Key Strengths (NKTR)
- Strong liquidity position with $149.6M cash providing near-term runway
- Low leverage ratio of 0.23x Debt/Equity provides financial flexibility
- Solid stockholders equity base of $576.2M from accumulated investment
- Strong current and quick ratios (4.97x) support near-term payables coverage
- Very low capex ($171K) implies operational flexibility and low capital intensity
- Assets exceed liabilities with positive book equity ($89.8M)
NKTR Stock Risks: Nektar Therapeutics Investment Risks
- Catastrophic revenue decline of 43.9% YoY signals severe business deterioration
- Negative operating cash flow of $44.3M annually with unsustainable burn rate
- Extreme unprofitability with -359.6% operating margin and 5.7% gross margin indicating core business model failure
- Cash runway of only 3-4 years at current burn rate without profitability inflection
- EPS deterioration (-$1.82) despite net losses narrowing, indicating worsening per-share economics
- Severe cash burn (OCF -$208.5M) versus limited cash ($15.1M) threatens runway
- Structural unprofitability with 1.1% gross margin and -253.7% operating margin
- Elevated leverage (Debt/Equity 1.49x) and no interest coverage increase refinancing risk
Key Metrics to Watch
- Quarterly revenue trends to confirm stabilization or continued collapse
- Gross margin improvement and operating expense rationalization progress
- Monthly cash burn rate and projected runway depletion date
- Product pipeline progress and regulatory approvals driving potential revenue recovery
- Operating cash flow (burn rate/runway)
- Revenue growth and gross margin trajectory
Nektar Therapeutics (NKTR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.21x current ratio provides a solid financial cushion.
NKTR Profit Margin, ROE & Profitability Analysis
NKTR vs Healthcare Sector: How Nektar Therapeutics Compares
How Nektar Therapeutics compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nektar Therapeutics Stock Overvalued? NKTR Valuation Analysis 2026
Based on fundamental analysis, Nektar Therapeutics has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nektar Therapeutics Balance Sheet: NKTR Debt, Cash & Liquidity
NKTR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nektar Therapeutics's revenue has declined by 36% over the 5-year period, indicating business contraction. The most recent EPS of $-8.68 indicates the company is currently unprofitable.
NKTR Revenue Growth, EPS Growth & YoY Performance
NKTR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.5M | -$44.9M | $-1.82 |
| Q3 2025 | $11.8M | -$35.5M | $-1.87 |
| Q2 2025 | $11.2M | -$41.6M | $-2.95 |
| Q1 2025 | $10.5M | -$36.8M | $-0.19 |
| Q3 2024 | $24.1M | -$37.1M | $-0.18 |
| Q2 2024 | $20.5M | -$51.1M | $-0.25 |
| Q1 2024 | $21.6M | -$36.8M | $-0.19 |
| Q3 2023 | $23.6M | -$45.8M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nektar Therapeutics Dividends, Buybacks & Capital Allocation
NKTR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nektar Therapeutics (CIK: 0000906709)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NKTR
What is the AI rating for NKTR?
Nektar Therapeutics (NKTR) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NKTR's key strengths?
Claude: Strong liquidity position with $149.6M cash providing near-term runway. Low leverage ratio of 0.23x Debt/Equity provides financial flexibility. ChatGPT: Strong current and quick ratios (4.97x) support near-term payables coverage. Very low capex ($171K) implies operational flexibility and low capital intensity.
What are the risks of investing in NKTR?
Claude: Catastrophic revenue decline of 43.9% YoY signals severe business deterioration. Negative operating cash flow of $44.3M annually with unsustainable burn rate. ChatGPT: Severe cash burn (OCF -$208.5M) versus limited cash ($15.1M) threatens runway. Structural unprofitability with 1.1% gross margin and -253.7% operating margin.
What is NKTR's revenue and growth?
Nektar Therapeutics reported revenue of $10.9M.
Does NKTR pay dividends?
Nektar Therapeutics does not currently pay dividends.
Where can I find NKTR SEC filings?
Official SEC filings for Nektar Therapeutics (CIK: 0000906709) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NKTR's EPS?
Nektar Therapeutics has a diluted EPS of $-1.82.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NKTR's fundamental grade?
Based on our AI fundamental analysis in May 2026, Nektar Therapeutics has a D grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NKTR stock overvalued or undervalued?
Valuation metrics for NKTR: ROE of -7.8% (sector avg: 15%), net margin of -413.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NKTR's AI grade for 2026?
Our dual AI analysis gives Nektar Therapeutics a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NKTR's free cash flow?
Nektar Therapeutics's operating cash flow is $-44.3M, with capital expenditures of $18.0K. FCF margin is -408.0%.
How does NKTR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -413.4% (avg: 12%), ROE -7.8% (avg: 15%), current ratio 10.21 (avg: 2).